Could put out fantastic news and not move up in price. Im holding on thinking Ocular is the future for this company. 60 Percent of a 4 billion dollar annual treatment for AMD is worth alot. The question is how long before Genentech AKA Roche sits on the sidelines and lets Lpath kick their but in Phase 2. Better watch out Goliath, here comes David.